Roche's CT-388 Shows 18.8% Mean Weight Loss in Phase Ib Trial

Roche's CT-388 Shows 18.8% Mean Weight Loss in Phase Ib Trial

Hiroko Sato
2 min read

Roche's New Therapy CT-388 Shows Promise in Treating Obesity and Type 2 Diabetes

Roche's recent Phase Ib trial for CT-388, a dual GLP-1 and GIP receptor agonist, has demonstrated encouraging results, with participants achieving an average placebo-adjusted weight loss of 18.8% at 24 weeks. This innovative once-weekly subcutaneous injection, designed to activate both GLP-1 and GIP receptors, aims to address the challenges of obesity and type 2 diabetes.

Following the announcement, Roche's shares surged by over 3.5% on the Swiss stock market, indicating a positive market response to the potential of CT-388. Notably, Eli Lilly's Mounjaro, a similar therapy, has already generated substantial sales, amounting to $1.81 billion in the first quarter of this year.

While the trial results are promising, it's important to note that common side effects of CT-388 include mild to moderate gastrointestinal-related adverse events. However, with the projected growth of the GLP-1 receptor agonist sales for the treatment of type 2 diabetes and obesity markets estimated to reach over $125 billion by 2033, the potential market impact of CT-388 is significant.

Key Takeaways

  • Roche’s CT-388 shows significant weight loss in Phase Ib trial for participants with obesity and type 2 diabetes
  • Positive market response with over 3.5% increase in Roche's shares after the trial announcement
  • Substantial sales generated by similar therapies like Eli Lilly's Mounjaro
  • Projected growth of the GLP-1 receptor agonist sales, reaching over $125 billion by 2033
  • Growing investment by pharmaceutical companies such as AstraZeneca and Novo Nordisk in developing obesity treatment pipelines


Roche's successful Phase Ib trial for CT-388 has the potential to disrupt the market, especially considering the projected substantial growth in the GLP-1 receptor agonist sales for the treatment of type 2 diabetes and obesity markets.

Did You Know?

  • GLP-1/GIP Receptor Agonist (CT-388): This novel medication developed by Roche aims to address obesity and type 2 diabetes by activating both GLP-1 and GIP receptors, regulating blood sugar levels, insulin secretion, and appetite.
  • Phase Ib Trial: This phase of clinical trials focuses on determining the efficacy and side effects of a new treatment in a larger group of participants. In the case of CT-388, it demonstrated an impressive 18.8% placebo-adjusted weight loss.
  • GLP-1 Obesity Therapies and Market: These therapies work by mimicking the functions of the body's natural GLP-1 hormone, controlling blood sugar levels and appetite. The GLP-1 obesity therapy market is projected to reach over $125 billion by 2033, highlighting the increasing demand for effective weight management solutions.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings